成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

瑞士Molecular Partners  


Molecular Partners is a privately owned biopharmaceutical company, located in Zurich, Switzerland, that is pioneering the development of a novel class of targeted protein therapeutics termed DARPins. DARPins are as target specific and potent as monoclonal antibodies. Yet, being small proteins, they overcome the known limitations of conventional protein-based therapeutic approaches.

We address real medical needs and develop cutting-edge medicine based on innovative DARPin products.

The DARPin platform has rapidly generated a differentiated pipeline of drug candidates. The most advanced DARPin is MP0112, an inhibitor of VEGF, which has completed two separate Phase I/IIa clinical trials in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), the most common causes for vision loss. Further products are in research and preclinical development. We balance our internal drug development efforts with strategic alliances with renowned pharmaceutical companies.

Molecular Partners is backed by a very strong international syndicate of institutional and corporate investors.